MSCO | QNA

Thank your for your time!

Q1. Blood-based(liquid) biopsy may overcome some limitations of solid tissue biopsy, including ______________

A: The patient has insufficient, inadequate or exhausted solid tissue 0%

B: Complementary informations to prior or future tissue testing is needed 0%

C: Disease progression or resistance mutations are suspected 0%

D: All of the above 0%

(Speaker slide: 02:53)

Q2. The amount of ctDNA released into the blood depends on _____________?

A: tumor grade, histology and vascularity 0%

B: physiological clearance and degradation 0%

C: time of blood draw and therapy 0%

D: All of the above 0%

(Speaker slide: 09:14)

Q3. Tissue biopsy may not capture the genomic landscape of a patient’s entire tumor burden due to ______________.

A: Intratumor heterogeneity 0%

B: Intrapatient heterogeneity 0%

C: Histological heterogeneity 0%

D: A and B 0%

“Tissue biopsy may not capture subclonal populations of tumor cells with distinct alterations.

Tissue biopsy from a single lesion will miss alterations unique to other lesions”

(Scherer, F. (2020) in Recent Results in Cancer Research: tumor Liquid Biopsies. Springer.)

Q4. What is tumor-agnostic therapy

A: Cancer therapies target genomic alterations causing cancer, regardless of where the cancer is located in the body 0%

B: Cancer treatment that uses drugs or other substances to precisely identify and attack certain types of cancer cells 0%

C: Cancer treatment that helps your immune system fight cancer 0%

D: None of the above 0%

“Tumor-agnostic (also known as histology-independent) cancer therapies target genomic alterations causing cancer, regardless of where the cancer is located in the body

(Offin M. et al., Am Soc Clin Oncol Educ Book, 2018, 38: 184-187)

Q5. Liquid biopsy-based NGS assays are useful in identifying actionable driver mutations in ___________ patients?

A: HER2 overexpression 0%

B: ALK mutations 0%

C: cancer with unknown primary 0%

D: KRAS mutations 0%

“These results show that liquid biopsy-based NGS assays are useful in identifying actionable driver mutations in CUP patients”

(Weipert, C., et al. (2020) ASCO presentation 105)